The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 1, 2012, Pages 7-14

  Green, Torrance ^a   Gonzalez, Alexis A ^a   Mitchell, Kenneth D ^a   Gabriel Navar, L ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

angiotensin converting enzyme; hypertension; renal prostaglandins; renin angiotensin system; salt restriction

Indexed keywords

ANGIOTENSIN II; CYCLOOXYGENASE 2; ELECTROLYTE; NIMESULIDE; PRORENIN RECEPTOR; PROSTACYCLIN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTANOID; RENIN;

BLOOD PRESSURE; CHRONIC DRUG ADMINISTRATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULUS; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY TUBULE ABSORPTION; KIDNEY VASCULAR RESISTANCE; MACULA DENSA; MEAN ARTERIAL PRESSURE; METABOLITE; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SALT INTAKE; SODIUM EXCRETION; SODIUM RESTRICTION; VASCULAR RESISTANCE; VASODILATATION; WATER ABSORPTION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 83055186454     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834d9d75     Document Type: Review

References (64)

1. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension 2011; 57:355-362.
2. Wolf G. The renin-angiotensin system and progression of renal diseases. Hamburg: Karger; 2002. pp. 1-268.
3. Mitchell KD, Botros FT, Navar LG. Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension. Acta Physiol Hung 2007; 94:31-48.
4. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001; 281:F1-F11.
5. Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2008; 294:F205-F211.
6. Opay AL, Mouton CR, Mullins J, Mitchell KD. Cyclooxygenase-2 inhibition normalized arterial blood pressure in CYP1A1-Ren2 transgenic rats with inducible Ang II-dependent malignant hypertension. Am J Physiol Renal Physiol 2006; 291:F612-F618. (Pubitemid 44343743)
7. Cheng H, Fan X, Guan Y, et al. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol 2009; 20:1953-1962.
8. Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 2010; 21:1678-1690.
9. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J Clin Invest 2002; 110:61-69. (Pubitemid 34743466)
10. Francois H, Facemire C, Kumar A, et al. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007; 18:1466-1475. (Pubitemid 46717513)
11. Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002; 61:1210-1219. (Pubitemid 34304481)
12. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741. (Pubitemid 29191226)
13. Zhang MZ, Yao B, Cheng HF, et al. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci USA 2006; 103:16045-16050. (Pubitemid 44657589)
14. Harris RC. An update on cyclooxygenase-2 expression and metabolites in the kidney. Curr Opin Nephrol Hypertens 2008; 17:64-69. (Pubitemid 350295199)
15. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002; 89:10D-17D. (Pubitemid 34241483)
16. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998; 274:F481-F489.
17. Peti-Peterdi J, Komlosi P, Fuson AL, et al. Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells. J Clin Invest 2003; 112:76-82. (Pubitemid 38056378)
18. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997; 30 (Part 2):687-692. (Pubitemid 27444256)
19. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008; 70:357-377. (Pubitemid 351738184)
20. Gonzalez AA, Cespedes C, Villanueva S, et al. E Prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. Biochem Biophys Res Commun 2009; 389:372-377.
21. Zewde T, Mattson DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 2004; 44:424-428. (Pubitemid 39281490)
22. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 2010; 299:F155-F166.
23. Matzdorf C, Kurtz A, Hocherl K. COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys. Am J Physiol Renal Physiol 2007; 292:F1782-F1790. (Pubitemid 47105368)
24. Fuson AL, Komlosi P, Unlap TM, et al. Immunolocalization of a microsomal prostaglandin E synthase in rabbit kidney. Am J Physiol Renal Physiol 2003; 285:F558-F564. (Pubitemid 37010867)
25. Kim SM, Chen L, Mizel D, et al. Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol 2007; 292:F415-F422. (Pubitemid 46105279)
26. Yang T, Park JM, Arend L, et al. Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem 2000; 275:37922-37929. (Pubitemid 32004912)
27. Ichihara A, Imig JD, Inscho EW, Navar L. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. Am J Physiol Renal Physiol 1998; 275:F605-F612.
28. Badzynska B, Sadowski J. Opposed effects of prostaglandin E2 on perfusion of rat renal cortex and medulla: interactions with the renin-angiotensin system. Exp Physiol 2008; 93:1292-1302.
29. Araujo M, Welch WJ. Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide. Am J Physiol Renal Physiol 2009; 296:F790-F794.
30. Deng A, Wead LM, Blantz RC. Temporal adaptation of tubuloglomerular feedback: effects of COX-2. Kidney Int 2004; 66:2348-2353. (Pubitemid 41115299)
31. Araujo M, Welch WJ. Tubuloglomerular feedback is decreased in COX-1 knockout mice after chronic angiotensin II infusion. Am J Physiol Renal Physiol 2010; 298:F1059-F1063.
32. + exchanger NHE2. Am J Physiol Renal Physiol 2008; 294:F937-F944.
33. Kammerl MC, Nusing RM, Seyberth HW, et al. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch 2001; 442:842-847. (Pubitemid 32900443)
34. Hocherl K, Kammerl M, Kees F, et al. Role of renal nerves in stimulation of renin, COX-2, and nNOS in rat renal cortex during salt deficiency. Am J Physiol Renal Physiol 2002; 282:F478-F484. (Pubitemid 34654537)
35. Zhang MZ, Yao B, Fang X, et al. Intrarenal dopaminergic system regulates renin expression. Hypertension 2009; 53:564-570.
36. Arendshorst WJ, Navar LG. Renal circulation and glomerular hemodynamics. In: Schrier RW, editor. Diseases of the kidney and urinary tract. Philadelphia: Lippincott Williams & Wilkins; 2007; pp. 54-95.
37. Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000; 36:276-281. (Pubitemid 30627000)
38. Roig F, Llinas MT, Lopez R, Salazar FJ. Role of cyclooxygenase-2 in the prolonged regulation of renal function. Hypertension 2002; 40:721-728. (Pubitemid 35278610)
39. Vaneckova I, Cahova M, Kramer HJ, et al. Acute effects of cyclooxygenase-2 inhibition on renal function in heterozygous ren-2-transgenic rats on normal or low sodium intake. Kidney Blood Press Res 2004; 27:203-210. (Pubitemid 39279324)
40. Green T, Rodriguez J, Navar LG. Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II. Am J Physiol Renal Physiol 2010; 299:F954-F962.
41. Salazar FJ, Llinas MT. Renal hemodynamic effects elicited by acute cyclooxygenase-2 inhibition are not related to angiotensin II levels. Am J Physiol Renal Physiol 2010; 299:F952-F953.
42. Okumura T, Hayashi I, Ikezawa T, et al. Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens Res 2002; 25:927-938. (Pubitemid 36024650)
43. Richter CM, Godes M, Wagner C, et al. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens 2004; 22:191-198. (Pubitemid 38293547)
44. Welch WJ, Patel K, Modlinger P, et al. Roles of vasoconstrictor prostaglandins, COX-1 and-2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension. Am J Physiol Heart Circ Physiol 2007; 293:H2644-H2649. (Pubitemid 350106484)
45. Wang J-L, Cheng H-F, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101. (Pubitemid 29325725)
46. Boshra V, El Wakeel GA, Nader MA. Effect of celecoxib on the antihypertensive effect of losartan in a rat model of renovascular hypertension. Can J Physiol Pharmacol 2011; 89:103-107.
47. Kose F, Besen A, Paydas S, et al. Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats. Clin Exp Nephrol 2010; 14:22-27.
48. Krattinger N, Alonso F, Capponi A, et al. Increased expression of renal cyclooxygenase-2 and neuronal nitric oxide synthase in hypertensive Cx40-deficient mice. J Vasc Res 2009; 46:188-198.
49. Jaimes EA, Tian RX, Pearse D, Raij L. Up-regulation of glomerular COX-2 by angiotensin II: role of reactive oxygen species. Kidney Int 2005; 68:2143-2153. (Pubitemid 43117788)
50. Jaimes EA, Zhou MS, Pearse DD, et al. Upregulation of cortical COX-2 in saltsensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol 2008; 294:F385-F392. (Pubitemid 351199404)
51. Howard LL, Patterson ME, Mullins JJ, Mitchell KD. Salt-sensitive hypertension develops after transient induction of ANG II-dependent hypertension in Cyp1a1-Ren2 transgenic rats. Am J Physiol Renal Physiol 2005; 288: F810-F815. (Pubitemid 40381750)
52. Kopkan L, Huskova Z, Vanourkova Z, et al. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vasc Pharmacol 2009; 51:175-181.
53. Kumar BL, Addepalli V. Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats. Ren Fail 2011; 33:72-78.
54. Vogt L, de Zeeuw D, Woittiez AJ, Navis G. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. Nephrol Dial Transplant 2009; 24:1182-1189.
55. Quilley J, Santos M, Pedraza P. Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol 2011; 300:H2316-H2322.
56. Cherney DZ, Miller JA, Scholey JW, et al. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 2008; 57:688-695.
57. Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001; 107:889-898. (Pubitemid 32274042)
58. Yabuki A, Taniguchi K, Yamato O. Immunohistochemical examination of cyclooxygenase-2 and renin in a KK-A(y) mouse model of diabetic nephropathy. Exp Anim 2010; 59:479-486.
59. Srivastava T, McCarthy ET, Sharma R, et al. Prostaglandin E(2) is crucial in the response of podocytes to fluid flow shear stress. J Cell Commun Signal 2010; 4:79-90.
60. Cherney DZ, Scholey JW, Nasrallah R, et al. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2008; 294:F1336-F1341.
61. Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70:641-646. (Pubitemid 44215337)
62. Naito M, Shenoy A, Aoyama I, et al. High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol 2009; 30:99-111.
63. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology 2009; 150:5557-5565.
64. Jaimes EA, Hua P, Tian RX, Raij L. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol 2010; 298:F125-F132.